Core Viewpoint - Brompton Split Banc Corp. has renewed its at-the-market equity program to issue Class A and Preferred Shares, replacing the previous program established in April 2023 [1][2]. Group 1: ATM Program Details - The renewed ATM Program allows the Fund to issue shares at prevailing market prices through the Toronto Stock Exchange or other Canadian marketplaces, with maximum gross proceeds of $75 million for each share class [2][3]. - The program will be effective until June 22, 2027, unless terminated earlier by the Fund, and the volume and timing of distributions will be at the Fund's discretion [3]. Group 2: Investment Portfolio - The Fund invests in a portfolio consisting of common shares of the six largest Canadian banks, with the option to hold up to 10% of total assets in global financial companies for diversification [4]. Group 3: Investment Objectives - The investment objective for Class A Shares is to provide regular monthly cash distributions targeted at least at $0.10 per share and growth in net asset value [5]. - The investment objective for Preferred Shares is to provide fixed cumulative preferential quarterly cash distributions of $0.15625 per share (6.25% per annum) and return the original issue price by November 29, 2027 [6]. Group 4: Performance Metrics - Over the last 10 years, Class A Shares have delivered a 12.0% per annum total return based on NAV, outperforming the S&P/TSX Composite Total Return Index by 3.7% per annum [7][10]. - Preferred Shares have returned 5.3% per annum over the last 10 years, outperforming the S&P/TSX Preferred Share Total Return Index by 1.7% per annum [7][10].

SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced the pricing of its previously announced underwritten public offering of 2,222,222 shares of its common stock at a public offering price of $9.00 per share. In addition, Gyre has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 333,333 shares of its common stock at the p ...

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare and clinical stage drug development company, is pleased to announce it has closed the acquisition to acquire 100% of the issued and outstanding shares of NoBrainer Imaging Centers, Inc. VANCOUVER, British Columbia, May 22, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare and clinical stage drug developm ...

BOSTON, May 22, 2025 (GLOBE NEWSWIRE) -- CECOCECO, a leading innovator in the lighting and display industry, is excited to announce its participation in the AIA Conference on Architecture & Design 2025, taking place from June 4-7 in Boston. At Booth #1119, CECOCECO will present the latest edition of ArtMorph—an innovative luminous wall panel that seamlessly blends LED display technology with textures. Hosted by the American Institute of Architects (AIA), the conference is one of the industry's most influent ...

ROCKVILLE, Md. and SUZHOU, China, May 22, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, today announced that new clinical data from two ongoing investigational studies evaluating lisaftoclax in various blood cancers and alrizomadlin in solid tumors will be presented during an oral presentation and poster presentation, respectively, at the 2025 American Society of Clinical Oncology (ASCO) Annual ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new data from several studies of compounds discovered by HUTCHMED including savolitinib, ranosidenib, fruquintinib and surufatinib, will be presented at the American Society of Clinical Oncology (“ASCO”) Annual Meeting taking place on May 30 – June 3, 2025 in Chicago, USA. Results from the SACHI China Phase III study of savolitinib in combinat ...

AI-Media and Lightning International Partnership AI-Media and Lightning International Join Forces to Make FAST Channels Accessible to Everyone SYDNEY and HONG KONG, May 22, 2025 (GLOBE NEWSWIRE) -- AI-Media Technologies Limited ("AI-Media"), a global leader in live captioning and translation solutions, has entered a groundbreaking partnership with Lightning International ("Lightning"), the leading distributor of Free Ad-Supported Television (FAST) channels. This collaboration aims to break down barriers ...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, May 22, 2025 (GLOBE NEWSWIRE) -- Reeflex Solutions Inc. (TSXV: RFX) (formerly Bigstack Opportunities I Inc., a capital pool company) (“Reeflex”) is pleased to announce that it has successfully completed its previously announced “Qualifying Transaction” pursuant to TSX Venture Exchange (“TSXV”) Policy 2.4 – Capital Pool Companies (the “Qualifying Transaction”). Reeflex received conditional approval from ...

Group 1 - Imperial Metals Corporation held its virtual Annual and Special Meeting of Shareholders on May 21, 2025, where nominees listed in the management information circular dated April 4, 2025, were elected as directors [1] - A total of 116,456,204 common shares were voted, representing approximately 71.86% of the issued and outstanding common shares of the Company [2] - The election results showed high approval rates for the directors, with Carolyn D. Anglin receiving 99.97% of votes for, and J. Brian Kynoch receiving 99.99% [2] Group 2 - Imperial is based in Vancouver and is involved in exploration, mine development, and operations, with holdings including the Mount Polley mine (100%), Huckleberry mine (100%), and Red Chris mine (30%) [3] - The Company also has a portfolio of 23 greenfield exploration properties located in British Columbia [3]

Core Points - Swiss Water Decaffeinated Coffee Inc. held its Annual General Meeting of Shareholders on May 22, 2025, where key voting results were announced [1] Group 1: Election of Directors - All Director nominees listed in the Management Information Circular were elected as Directors of Swiss Water, with Frank A. Dennis receiving 98.58% support, and Eric Yanagi receiving 64.37% support [2] Group 2: Appointment of Auditors - MNP LLP was appointed as auditors with a significant voting support of 99.93% [3] Group 3: Company Overview - Swiss Water Decaffeinated Coffee Inc. is recognized as a leading specialty coffee company that utilizes the proprietary Swiss Water® Process for decaffeination without chemical solvents, and it also owns Seaforth Supply Chain Solutions Inc. [4]